Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,654.00-0.13%ETH$2,677.39-1.09%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
AR

NASDAQ · ARVN

Arvinas, Inc.

Healthcare · Biotechnology

$7.41

Down-$0.02 (-0.27%)

Updated Oct 4, 2026, 1:43 AM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
974.25M
P/E ratio
-10.66
Dividend yield
0.00%
52-week range
$6.97 – $14.51
Volume
585.12K
Avg. volume
876.56K

Price performance · ARVN

ARVN price history

1M range · 0 trading sessions · Daily adjusted prices

ARVN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ARVN news

The latest Smart Investors Daily articles mentioning ARVN.

Stock researchCompany · Overview

ARVN research

Overview

Company profile and research snapshot.

Company profile

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.20
Implied upside
—
Analysts
—
ARVN recent ratings
DateFirmRatingTarget
Aug 10, 2026Evercore ISI GroupOutperform—
Aug 10, 2026CitigroupBuy—
Aug 5, 2026WedbushNeutral—
Aug 5, 2026Wells FargoEqual-Weight—
Aug 4, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of September 28, 2026 (the “Gr

Yahoo · Sep 28, 2026

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC)

Benzinga · Sep 25, 2026

Arvinas Q2 2026 Earnings Call Transcript

Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By